Dyne Therapeutics (DYN) Stock Price, Quote, News & History

Comments

Dyne Therapeutics Inc (DYN) Stock Price, Quote, News & History

DYNNASDAQ

Trade with Public

$15.62

-0.57-3.52%

At close: Feb 27, 4:00 PM EST

$15.10

-0.52-3.33%

After Hours: 7:59 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$15.72

Close

$15.62

Volume / Avg.

1.93M / 2.43M

Day Range

$15.10 - $16.01

52 Wk Range

6.36 - 25.00

Market Cap

$2.49B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

12.78%

Days to Cover

11.52

Recent Dyne Therapeutics Inc News

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.

Vandana Singh

Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements

Dyne Therapeutics reported positive results from Phase 1/2 DELIVER trial for z-rostudirsen in DMD amenable to exon 51 skipping.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-375.71M

Investing Cash Flow (TTM)

-45.74M

Financing Cash Flow (TTM)

462.98M

Free Cash Flow (TTM)

-397.01M

Capital Expenditure (TTM)

-21.30M

Net Change in Cash (TTM)

41.53M

Analyst Trends and Forecast

0

Oct 25

2

1

Nov 25

6

Dec 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.00B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.86

Earnings Yield % (TTM)

-22.33%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.20

Company Debt

Total Debt

$99.15M

LT Debt

$99.15M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$573.61M

Debt to Equity

0.17

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$15.72

Close

$15.62

Volume / Avg.

1.93M / 2.43M

Day Range

$15.10 - $16.01

52 Wk Range

6.36 - 25.00

Market Cap

$2.49B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

12.78%

Days to Cover

11.52

About

Sector

Health Care

Industry

Biotechnology

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therape...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Dyne Therapeutics (DYN) stock?

A

You can purchase shares of Dyne Therapeutics (NASDAQ:DYN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Dyne Therapeutics (DYN) competitors?

A

Other companies in Dyne Therapeutics’s space includes: IDEAYA Biosciences Inc (NASDAQ:IDYA), Immunome Inc (NASDAQ:IMNM), Twist Bioscience Corp (NASDAQ:TWST), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) and Ascentage Pharma Group International (NASDAQ:AAPG).

Q

What is the forecast, or price target, for Dyne Therapeutics (DYN) stock?

A

Dyne Therapeutics has a consensus price target of $41.60.

Q

What is the current price for Dyne Therapeutics (DYN)?

A

The stock price for Dyne Therapeutics (NASDAQ: DYN) is $15.1 last updated February 27, 2026 at 7:59 PM EST.

Q

Does Dyne Therapeutics (DYN) pay a dividend?

A

There are no upcoming dividends for Dyne Therapeutics.

Q

When is Dyne Therapeutics (NASDAQ:DYN) reporting earnings?

A

Dyne Therapeutics does not have any upcoming earnings scheduled.

Q

Is Dyne Therapeutics (DYN) going to split?

A

There is no upcoming split for Dyne Therapeutics.

Q

What sector and industry does Dyne Therapeutics (DYN) operate in?

A

Dyne Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

IDEAYA Biosciences Inc

Twist Bioscience Corp

NASDAQ:TWST

$47.27

0.75%

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$23.40

0.04%

AAPG

Xenon Pharmaceuticals Inc

Kiniksa Pharmaceuticals International PLC

NASDAQ:KNSA

$44.49

%

Key Statistics

Open

$15.72

Close

$15.62

Volume / Avg.

1.93M / 2.43M

Day Range

$15.10 - $16.01

52 Wk Range

6.36 - 25.00

Market Cap

$2.49B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

12.78%

Days to Cover

11.52

Recent Dyne Therapeutics Inc News

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.

Vandana Singh

Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements

Dyne Therapeutics reported positive results from Phase 1/2 DELIVER trial for z-rostudirsen in DMD amenable to exon 51 skipping.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-375.71M

Investing Cash Flow (TTM)

-45.74M

Financing Cash Flow (TTM)

462.98M

Free Cash Flow (TTM)

-397.01M

Capital Expenditure (TTM)

-21.30M

Net Change in Cash (TTM)

41.53M

Analyst Trends and Forecast

0

Oct 25

2

1

Nov 25

6

Dec 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.00B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.86

Earnings Yield % (TTM)

-22.33%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.20

Company Debt

Total Debt

$99.15M

LT Debt

$99.15M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$573.61M

Debt to Equity

0.17

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$15.72

Close

$15.62

Volume / Avg.

1.93M / 2.43M

Day Range

$15.10 - $16.01

52 Wk Range

6.36 - 25.00

Market Cap

$2.49B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

12.78%

Days to Cover

11.52

About

Sector

Health Care

Industry

Biotechnology

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therape...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry